*Each BIKTARVY® 50 mg/200 mg/25 mg film-coated tablet is approximately 15 mm x 8 mm.^1,2 

†Interaction studies have only been performed in adults. BIKTARVY® should not be administered concomitantly with medicinal products containing TAF, tenofovir disoproxil, 3TC or adefovir dipivoxil used for the treatment of HBV infection.^1,2 

BIKTARVY® is indicated for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.^1,2

Contraindications: BIKTARVY® should not be co-administered with rifampicin and St. John’s wort, or given to people living with HIV who have hypersensitivity to the active substances or to any of the excipients.^1,2

Please refer to the BIKTARVY® Summary of Product Characteristics for information on medications that could require specific management when co-administered.

*BIKTARVY® should not be co-administered simultaneously with antacids, oral medications or supplements containing magnesium, aluminium or iron under fasted conditions. BIKTARVY® should be administered at least 2 hours before, or with food 2 hours after antacids, oral medications or supplements containing magnesium and/or aluminium.  BIKTARVY® should be administered at least 2 hours before iron supplements, or taken together with food at any time. In pregnant patients, dosage adjustments are recommended for co-administration of polyvalent cation-containing antacids, oral medications or supplements (including calcium-containing oral medications or supplements). See SmPC for full information, including use during pregnancy.^1,2

†In patients with moderate renal impairment, close monitoring should be considered when starting co-administration of BIKTARVY® with metformin, in line with the metformin SmPC.

Nephrotoxicity: Post-marketing cases of renal impairment, including acute renal failure and proximal renal tubulopathy (PRT) reported with TAF-containing products. A potential risk of nephrotoxicity resulting from chronic exposure low tenofovir exposure with TAF cannot be excluded. It is recommended that renal function is assessed prior to, or when initiating, TAF and is monitored during therapy in all patients as clinically appropriate. If clinically significant decreases in renal function, or evidence of PRT occur, consider discontinuation of TAF.